The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
VAXCYTE INC COM 92243G108 59,064 2,222,970 SH   DFND 1 0 2,222,970 0
ENTASIS THERAPEUTICS HLDGS I COM 293614103 2,915 1,180,178 SH   DFND 1 0 1,180,178 0
INOZYME PHARMA INC COM 45790W108 32,841 1,591,154 SH   DFND 1 0 1,591,154 0
KARUNA THERAPEUTICS INC COM 48576A100 110,057 1,083,344 SH   DFND 1 0 1,083,344 0
ARCUTIS BIOTHERAPEUTICS INC COM 03969K108 18,895 671,716 SH   DFND 1 0 671,716 0
ALIGOS THERAPEUTICS INC COM 01626L105 24,237 876,548 SH   DFND 1 0 876,548 0
AKOUOS INC COM 00973J101 35,577 1,794,088 SH   DFND 1 0 1,794,088 0
FUSION PHARMACEUTICALS INC COM 36118A100 18,781 1,598,379 SH   DFND 1 0 1,598,379 0
ITERUM THERAPEUTICS PLC SHS G6333L101 935 945,085 SH   DFND 1 0 945,085 0